ADAM—15在WHOⅠ级脑膜瘤中的表达及其与侵袭性的相关研究(4)
[12] Xie B，Shen J，Dong A，et al.An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization[J].Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology，2008，22(8)：2775-2783.
[13] Horiuchi K，Weskamp G，Lum L，et al.Potential role for ADAM15 in pathological neovascularization in mice[J].Molecular & Cellular Biology，2003，23(16)：5614-5624.
[14] Moore M J，Hamm J，Dancey J，et al.Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas：a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J].Clin Oncol，2003，21(17)：3296-3302.
[15] Nuti E，Tuccinardi T，Rossello A.Matrix metalloproteinase inhibitors：new challenges in the era of post broad-spectrum inhibitors[J].Current Pharmaceutical Design，2007，13(20)：2087-2100.
[16] Mant T G K，Bradford D，Amin D M，et al.Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304，a novel matrix metalloproteinase inhibitor，in healthy volunteers[J].British Journal of Clinical Pharmacology，2007，63(5)：512-526.
[17] Nuti E，Cantelmo A R，Gallo C，et al.N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors： Hit Selection and in Vivo Antiangiogenic Activity[J].Journal of Medicinal Chemistry，2015，58(18)：7224-7240.
[18] Ep V D V，Keijbeck A A，de Winther M P，et al.A disintegrin and metalloproteases：molecular scissors in angiogenesis，inflammation and atherosclerosis[J].Atherosclerosis，2012，224(2)：302-308.
[19] Sch?nefu? A，Abety A N，Zamek J，et al.Role of ADAM-15 in wound healing and melanoma development[J].Experimental Dermatology，2012，21(6)：437-442.
[20] Thathiah A，Carson D D.MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17[J].Biochemical Journal，2004，382(1)：363-373.
[21] Moali C，Hulmes D J.Extracellular and cell surface proteases in wound healing： new players are still emerging[J].European Journal of Dermatology，2009，19(6)：552-564.
(收稿日期：2017-11-09) (本文編辑：张爽), 百拇医药(赵昌通 刘妙铮 张世华 王浩岩 杨德森)
[13] Horiuchi K，Weskamp G，Lum L，et al.Potential role for ADAM15 in pathological neovascularization in mice[J].Molecular & Cellular Biology，2003，23(16)：5614-5624.
[14] Moore M J，Hamm J，Dancey J，et al.Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas：a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J].Clin Oncol，2003，21(17)：3296-3302.
[15] Nuti E，Tuccinardi T，Rossello A.Matrix metalloproteinase inhibitors：new challenges in the era of post broad-spectrum inhibitors[J].Current Pharmaceutical Design，2007，13(20)：2087-2100.
[16] Mant T G K，Bradford D，Amin D M，et al.Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304，a novel matrix metalloproteinase inhibitor，in healthy volunteers[J].British Journal of Clinical Pharmacology，2007，63(5)：512-526.
[17] Nuti E，Cantelmo A R，Gallo C，et al.N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors： Hit Selection and in Vivo Antiangiogenic Activity[J].Journal of Medicinal Chemistry，2015，58(18)：7224-7240.
[18] Ep V D V，Keijbeck A A，de Winther M P，et al.A disintegrin and metalloproteases：molecular scissors in angiogenesis，inflammation and atherosclerosis[J].Atherosclerosis，2012，224(2)：302-308.
[19] Sch?nefu? A，Abety A N，Zamek J，et al.Role of ADAM-15 in wound healing and melanoma development[J].Experimental Dermatology，2012，21(6)：437-442.
[20] Thathiah A，Carson D D.MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17[J].Biochemical Journal，2004，382(1)：363-373.
[21] Moali C，Hulmes D J.Extracellular and cell surface proteases in wound healing： new players are still emerging[J].European Journal of Dermatology，2009，19(6)：552-564.
(收稿日期：2017-11-09) (本文編辑：张爽), 百拇医药(赵昌通 刘妙铮 张世华 王浩岩 杨德森)